999 related articles for article (PubMed ID: 19351682)
1. Quantitative proteomics for drug toxicity.
Gao Y; Holland RD; Yu LR
Brief Funct Genomic Proteomic; 2009 Mar; 8(2):158-66. PubMed ID: 19351682
[TBL] [Abstract][Full Text] [Related]
2. Toxicoproteomics: new paradigms in toxicology research.
George J; Singh R; Mahmood Z; Shukla Y
Toxicol Mech Methods; 2010 Sep; 20(7):415-23. PubMed ID: 20175663
[TBL] [Abstract][Full Text] [Related]
3. Molecular biomarkers in drug development.
Lewin DA; Weiner MP
Drug Discov Today; 2004 Nov; 9(22):976-83. PubMed ID: 15539141
[TBL] [Abstract][Full Text] [Related]
4. Proteomics: recent applications and new technologies.
Elrick MM; Walgren JL; Mitchell MD; Thompson DC
Basic Clin Pharmacol Toxicol; 2006 May; 98(5):432-41. PubMed ID: 16635100
[TBL] [Abstract][Full Text] [Related]
5. Mathematical biodescriptors of proteomics maps: background and applications.
Basak SC; Gute BD
Curr Opin Drug Discov Devel; 2008 May; 11(3):320-6. PubMed ID: 18428085
[TBL] [Abstract][Full Text] [Related]
6. Novel biomarkers of acute kidney toxicity.
Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
[TBL] [Abstract][Full Text] [Related]
7. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.
Calvo KR; Liotta LA; Petricoin EF
Biosci Rep; 2005; 25(1-2):107-25. PubMed ID: 16222423
[TBL] [Abstract][Full Text] [Related]
8. Molecular approaches to the identification of biomarkers of exposure and effect--report of an expert meeting organized by COST Action B15. November 28, 2003.
Gundert-Remy U; Dahl SG; Boobis A; Kremers P; Kopp-Schneider A; Oberemm A; Renwick A; Pelkonen O
Toxicol Lett; 2005 Apr; 156(2):227-40. PubMed ID: 15737486
[TBL] [Abstract][Full Text] [Related]
9. Proteomic approaches in biological and medical sciences: principles and applications.
Conrotto P; Souchelnytskyi S
Exp Oncol; 2008 Sep; 30(3):171-80. PubMed ID: 18806738
[TBL] [Abstract][Full Text] [Related]
10. From proteins to proteomics.
Bradshaw RA; Burlingame AL
IUBMB Life; 2005; 57(4-5):267-72. PubMed ID: 16036609
[TBL] [Abstract][Full Text] [Related]
11. Promises of biomarkers in drug development--a reality check.
Marrer E; Dieterle F
Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
[TBL] [Abstract][Full Text] [Related]
12. The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.
Ferrer-Alcón M; Arteta D; Guerrero MJ; Fernandez-Orth D; Simón L; Martinez A
Toxicol Lett; 2009 Apr; 186(1):45-51. PubMed ID: 19022361
[TBL] [Abstract][Full Text] [Related]
13. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
15. Application of genomics in preclinical drug safety evaluation.
Lord PG; Nie A; McMillian M
Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814
[TBL] [Abstract][Full Text] [Related]
16. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
Kramer JA; Sagartz JE; Morris DL
Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
[TBL] [Abstract][Full Text] [Related]
17. Proteomic methods for drug target discovery.
Sleno L; Emili A
Curr Opin Chem Biol; 2008 Feb; 12(1):46-54. PubMed ID: 18282485
[TBL] [Abstract][Full Text] [Related]
18. Approaching clinical proteomics: current state and future fields of application in cellular proteomics.
Apweiler R; Aslanidis C; Deufel T; Gerstner A; Hansen J; Hochstrasser D; Kellner R; Kubicek M; Lottspeich F; Maser E; Mewes HW; Meyer HE; Müllner S; Mutter W; Neumaier M; Nollau P; Nothwang HG; Ponten F; Radbruch A; Reinert K; Rothe G; Stockinger H; Tárnok A; Taussig MJ; Thiel A; Thiery J; Ueffing M; Valet G; Vandekerckhove J; Wagener C; Wagner O; Schmitz G
Cytometry A; 2009 Oct; 75(10):816-32. PubMed ID: 19739086
[TBL] [Abstract][Full Text] [Related]
19. Enhanced detectability in proteome studies.
Sriyam S; Sinchaikul S; Tantipaiboonwong P; Tzao C; Phutrakul S; Chen ST
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 849(1-2):91-104. PubMed ID: 17140866
[TBL] [Abstract][Full Text] [Related]
20. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery.
Fischer HP
Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
